{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Batteson R"],"funding":["the healthcare business of Merck KGaA, Darmstadt, Germany","NCI NIH HHS"],"pagination":["191-201"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10963552"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(2)"],"pubmed_abstract":["<h4>Background</h4>Patients with non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 (METex14) skipping typically demonstrate poorer prognosis than overall non-small cell lung cancer. Until recently, no targeted treatments were available for patients with non-small cell lung cancer harbouring METex14 skipping in the UK, with limited treatments available.<h4>Objective</h4>This study estimates the long-term survival and quality-adjusted life-year benefit of MET inhibitor tepotinib versus current standard of care from a UK perspective.<h4>Methods</h4>A partitioned-survival model assessed the survival and quality-adjusted life-year benefits of tepotinib versus immunotherapy ± chemotherapy and chemotherapy for untreated and previously treated patients, respectively, "],"journal":["Targeted oncology"],"pubmed_title":["Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK."],"pmcid":["PMC10963552"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["McLean T","Hatswell AJ","Vioix H","Batteson R","Baijal S","Hook E","Alexopoulos ST","Paik PK","Wheat H"],"additional_accession":[]},"is_claimable":false,"name":"Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK.","description":"<h4>Background</h4>Patients with non-small cell lung cancer harbouring mesenchymal-epithelial transition exon 14 (METex14) skipping typically demonstrate poorer prognosis than overall non-small cell lung cancer. Until recently, no targeted treatments were available for patients with non-small cell lung cancer harbouring METex14 skipping in the UK, with limited treatments available.<h4>Objective</h4>This study estimates the long-term survival and quality-adjusted life-year benefit of MET inhibitor tepotinib versus current standard of care from a UK perspective.<h4>Methods</h4>A partitioned-survival model assessed the survival and quality-adjusted life-year benefits of tepotinib versus immunotherapy ± chemotherapy and chemotherapy for untreated and previously treated patients, respectively, ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-01T05:36:47.218Z","creation":"2026-04-08T09:38:37.327Z"},"accession":"S-EPMC10963552","cross_references":{"pubmed":["38492157"],"doi":["10.1007/s11523-024-01038-z"]}}